Premium
Susceptibility of dermatophyte isolates obtained from a large worldwide terbinafine tinea capitis clinical trial
Author(s) -
Ghannoum M.A.,
Wraith L.A.,
Cai B.,
Nyirady J.,
Isham N.
Publication year - 2008
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2008.08648.x
Subject(s) - dermatophyte , terbinafine , library science , tinea capitis , medicine , corporation , history , family medicine , dermatology , political science , computer science , antifungal , law , itraconazole
Summary Background Our group, in collaboration with seven other laboratories, has recently developed a method to determine the susceptibility of dermatophytes. Objectives The objective of this study was to determine the terbinafine susceptibility profile of dermatophyte isolates obtained from patients with tinea capitis enrolled in two large worldwide clinical trials and to investigate whether these susceptibilities differ by geographical location. Methods Susceptibilities were determined according to the Clinical and Laboratory Standards Institute M38‐A2 standard. Results From a total of 978 baseline dermatophyte isolates, we selected 301 isolates at random. These included: Trichophyton tonsurans ( n = 125) , Microsporum canis ( n = 94), T. violaceum ( n = 63) and M. audouinii ( n = 19) . The terbinafine minimum inhibitory concentration (MIC) range was 0·001–0·25 μg mL −1 , while MIC 50 and MIC 90 ranged between 0·002 and 0·125 μg mL −1 and 0·03 and 0·25 μg mL −1 , respectively, for all species tested. MIC 50 and MIC 90 varied by individual species; however, there was no difference in terbinafine MIC among the different species isolated from U.S. and non‐U.S. sites. Conclusion Terbinafine demonstrates potent antifungal activity against dermatophyte isolates obtained from patients with tinea capitis worldwide.